1Szcepanaki T, Langerak AW, Willemse M J, et al. T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia reflect end-stage recombinations: implications for minimal residual disease monitoring [J]. Leukemia, 2000,14(7):1208.
2Taube T,Seeger K,Beyermann B,et al. Multiplex PCR for simultaneous detection of the most frequent T cell receptor-delta gene rearrangements in childhood ALL[J]. Leukemia, 1997,11(11):1978.
3Mayer SP, Giamelli J, Sandoval C, et al. Quantitation of leukemia clone-specific antigen gene rearrangements by a single-step PCR and fluorescence-based detection method [J].Leukemia, 1999,13(11):1843.
4Cayuela JM,Baruchel A,Orange C ,et al. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precurser acute lymphoblastic leukemia [J]. Blood, 1996,88(1):302.
5Melec M, van der veldem VH, bjorklumd E, et al. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia:comparison between RQ-PCR analysis of Ig/TCR gene rearrangements and multicolor flow cytometric immunophenotyping[J].Leukemia,2004,18(10):1630.
6Jianbiao Z, Meredith AG, Aihong L, et al. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consoratium Protocol 95-01[J]. Blood,2007,110(5):1607
8Kerst G, Kreyenberg H, Roth C, et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukemia by flow cytometry and real-time PCR [J]. Br J Haematol,2005,128(6):774.
9Neale GA, Coustan-Smith E, Stow P, et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia[J]. Leukemia,2004,18(5):934.
10Cave H,Bosch J,Sucin S,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia[J]. N Engl J Med,1998,339(9):591.
2Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age [J]. Hematol Am Soc Hematol Educ Program, 2012,2012:35-42.
3Braggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials : proceedings of the Second International Symposium on MRD assessment in Kiel, Gemlany, 1 8- 20 September 2008[J]. Leukemia,2010,24( 3):521-535.
4Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of real-time quantitative reverse tran- scriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program[J]. Leukemia, 2003,17 (12) : 2318-2357.
5van Dongen JJ, van der Velden VH, Braggemann M, et al. Mini mal residual disease diagnostics in acute lymphoblastic leuke mia: need for sensitive, fast, and standardized technologies [J] Blood ,2015,125(26) : 3996-4009.
6Pongers-Willemse MJ, Verhagen OJ, Tibbe G J, et al. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes [ J ]. Leukemia, 1998,12 (12) : 2006-2014.
7Coustan-Smith E, Sancho J, Hancock ML, et al. Use of peripher- al blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia [J]. Blood, 2002, 100(7) :2399-2402.
8Coustan-Smith E, Song G, Clark C,et al. New markers for min- imal residual disease detection in acute lymphoblastic leuke- mia [ J ]. Blood, 2011,117 (23) : 6267-6276.
9Buceisano F, Maurillo L, Del Princ, ipe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia [ J ]. Blood, 2012, 119 (2) : 332-341.
10Conter V, Bartram CR, Valsecchi MG, et al. Molecular re- sponse to treatment redefines ALL prognostic factors in chil- dren and adolescents with B-cell precursor acute lymphoblas- tie leukemia: results in 3184 patients of the AIEOPBFM ALL 2000 study[J]. Blood ,2010, 115(16) :3206-3214.
